HOG pathway modulation is a determinant of echinocandin treatment failure in Candidozyma auris
Authors:
- Dimitrios SofrasDSDimitrios Sofras
- Stef JacobsSJStef Jacobs
- Anitra ZileAZAnitra Zile
- Austin MottolaAMAustin Mottola
- Alvis ZvirgzdinsAZAlvis Zvirgzdins
- Alicia PageauAPAlicia Pageau
- Giorgio BoccarellaGBGiorgio Boccarella
- Hugh GiffordHGHugh Gifford
- Vladislav BiriukovVBVladislav Biriukov
- Alexandre K. DubeADAlexandre K. Dube
- Louise WalkerLWLouise Walker
- Dhara Malavia-JonesDMDhara Malavia-Jones
Preprint
Abstract
Candidozyma auris is a rapidly emerging fungal pathogen whose drug-resistant profile poses a formidable challenge to antifungal treatment. Echinocandins are the recommended first-line therapy for invasive C. auris infections, but resistance to this drug class is on the rise. Here we show that, beyond resistance, C. auris can readily acquire genetically encoded echinocandin tolerance, a phenotype of slow but sustained growth and increased survival at concentrations above the minimum inhibitory concentration (MIC) that reflects incomplete maximal inhibition and a reduced Hill coefficient without an increase in MIC. Tolerance was therefore undetectable by standard clinical susceptibility testing, yet it significantly reduced treatment efficacy in an immunocompromised murine model of systemic infection. Genetic dissection revealed that tolerance arises through disruption of the high-osmolarity glycerol (HOG) mitogen-activated protein kinase (MAPK) pathway through the loss of function of Ssk1, Ssk2, Pbs2 or Hog1, or specific substitutions in Nik1. The disruption of the HOG pathway did not confer fitness or virulence defects in C. auris, and in Candida albicans and Nakaseomyces glabratus, it did not confer tolerance, suggesting a unique non-essential rewiring of this pathway in C. auris. Proteomic and cell-wall analyses linked tolerance to altered cell-wall remodelling during echinocandin exposure. Evolutionary modelling and deep sequencing of FKS1 hotspots in experimentally evolved populations showed that tolerance increases the rate at which resistance-conferring FKS1 hotspot substitutions emerge. Putative high-impact mutations in HOG pathway effectors in clinical isolates suggest that this phenotype occurs in patients, where it might reduce treatment efficacy or facilitate resistance emergence. This work therefore identifies HOG-mediated acquired tolerance as a hidden clinically relevant direct and indirect determinant of echinocandin treatment failure.Funding Information
- FWO (11PRR24N)
- FWO (11J8122N)
- FWO (12O1922N)
- FWO (JPIAMR-CycleDrug)
- KU Leuven (PDMT2/23/032)
- KU Leuven (C3/22/007)
- ERC (ERC-SyG-2020 951475)
- Berlin University Alliance (515_BUA_Proteomics)
- Latvian Council of Science (lzp‐2023/1‐0312)
- Medical Research Council Centre for Medical Mycology (MR/N006364/2)
- Medical Research Council Centre for Medical Mycology (MR/P501955/2)
- Medical Research Council Centre for Medical Mycology (MR/W502649/1)
- Medical Research Council Centre for Medical Mycology (MR/M026663/2)
- Medical Research Council Centre for Medical Mycology (MR/Y002164/1)
- Medical Research Council Centre for Medical Mycology (MR/N006364/2)
- Wellcome Trust (225303/Z/22/Z)
- Wellcome Trust (200208)
- Wellcome Trust (215599)
- Wellcome Trust (224323)
- NIHR Exeter Biomedical Research Centre
- National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre (BRC)
- Spanish Ministry of Science and Innovation (PID2025-176398OB-I00)
- MICIU/AEI (/10.13039/501100011033)
- MICIU/AEI (/10.13039/501100011033)
- FEDER (PLEC2023-010225)
- la Caixa Foundation (LCF/PR/HR21/00737)
- la Caixa Foundation (CI23-20260)
- la Caixa Foundation (LCF/PR/HR21/52410006)
- la Caixa Foundation (LCF/PR/GN18/50310010)
- Instituto de Salud Carlos III (CIBERINFEC CB21/13/00061- ISCIII-SGEFI/ERDF)
- Instituto de Salud Carlos III (DTS25/00141)
- European Commission (Horizon Europe-HORIZON-MSCA-2023-DN-01-01 (grant number 101168618).)
- Genome Canada and Genome Quebec (6569)
- Canada Research Chair in Cellular Systems and Synthetic Biology